Gilead Sciences, Inc. (NASDAQ:GILD) announced an agreement with Jounce Therapeutics, Inc. (NASDAQ:JNCE) to license JTX-1811, a monoclonal antibody designed to deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells. An Investigational New Drug (IND) application for JTX-1811 is due to be filed in 1H 2021. Gilead will make a $85m upfront payment and a $35m equity investment. Jounce is eligible for up to an additional $685m in milestone payments. Jounce shares closed up 56% to $7.53.
*************

FDA releases PDUFA VI program report on combination products

https://endpts.com/fda-releases-pduva-vi-prog...-products/